Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00235911
Status:
COMPLETED
Last Update Posted:
2011-01-24
First Post:
2005-10-07
Brief Title:
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Effects of Symbicort Single Inhaler Therapy on Bronchial Hyper Responsiveness Asthma Control and Safety in Mild to Moderate Asthmatics in General Practice Compared to Usual Care Therapy
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients as measured by PD20 histamine and to validate the Bronchial Hyperresponsiveness Questionnaire BHQ
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None